Skip to main content
Erschienen in: Archives of Dermatological Research 7/2006

01.01.2006 | Short Communication

Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese

verfasst von: Jia Hu Hao, Dong Qing Ye, Guo Qing Zhang, Hui Hui Liu, Hong Dai, Fen Huang, Fa Ming Pan, Hong Su, Ma Xia Dong, Hong Chen, Qian Wang, Xue Jun Zhang

Erschienen in: Archives of Dermatological Research | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

The aims of the present study are to evaluate the difference of the levels of soluble Fas (sFas) antigen between patients with systemic lupus erythematosus (SLE) and healthy controls and to explore whether sFas has a role in either the disease activity or the organ damage in SLE. Serum levels of sFas were measured in 40 Chinese patients with SLE and 15 age-, gender-, and race-matched healthy controls using double antibody ELISA. SLEDAI scores for disease activity were determined. Data of organ and tissue damage was obtained from clinical records. Serum sFas levels were significantly increased in both more active (mean=8043.8 pg/ml, P<0.001) and less active SLE patients (mean=4820.2 pg/ml, P<0.001) comparing to the healthy controls (mean=3253.4 pg/ml). There was also a significant difference in serum sFas levels between the more active SLE patients and less active SLE patients (P=0.04). But, the levels of sFas didn’t correlate with SLEDAI. There was a significant difference in the serum sFas levels between patients with and without CNS disease (mean=9582.6, 6634.5 pg/ml; P=0.007). The same was true when patients with and without renal disease (mean=10972.7, 6520.1 pg/ml; P=0.019), as well as serositis (mean=10385.3, 6709.1 pg/ml; P=0.005) were analyzed. sFas is elevated in sera of SLE patients, especially in patients with active SLE. The elevated levels of sFas in the sera of patients with SLE may be closely associated with damage to the kidneys, central nervous system and serosa. Serum sFas may serve as a predictor of some organ and tissue damage in SLE.
Literatur
1.
Zurück zum Zitat Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, del Olmo JA, Darnell A, Ingelmo M (2004) Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 33:217–230PubMedCrossRef Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, del Olmo JA, Darnell A, Ingelmo M (2004) Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 33:217–230PubMedCrossRef
2.
Zurück zum Zitat Bujan S, Ordi-Ros J, Paredes J, Mauri M, Matas L, Cortes J, Vilardell M (2003) Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 62859–62865 Bujan S, Ordi-Ros J, Paredes J, Mauri M, Matas L, Cortes J, Vilardell M (2003) Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 62859–62865
3.
Zurück zum Zitat Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed
4.
Zurück zum Zitat Al-Maini MH, Mountz JD, Al-Mohri HA, El-Ageb EM, Al-Riyami BM, Svenson KL, Zhou T, Richens ER (2000) Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132–139PubMedCrossRef Al-Maini MH, Mountz JD, Al-Mohri HA, El-Ageb EM, Al-Riyami BM, Svenson KL, Zhou T, Richens ER (2000) Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132–139PubMedCrossRef
5.
Zurück zum Zitat Bijl M, Horst G, Limburg PC, Kallenberg CG (2001) Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10:866–872PubMedCrossRef Bijl M, Horst G, Limburg PC, Kallenberg CG (2001) Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10:866–872PubMedCrossRef
6.
Zurück zum Zitat Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126–1129PubMedCrossRef Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126–1129PubMedCrossRef
7.
Zurück zum Zitat Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRef Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRef
8.
Zurück zum Zitat van der Linden MW, van Lopik T, Aarden LA, Westendorp RG, Huizinga TW (2001) Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis 60:237–241PubMedCrossRef van der Linden MW, van Lopik T, Aarden LA, Westendorp RG, Huizinga TW (2001) Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis 60:237–241PubMedCrossRef
9.
Zurück zum Zitat Silvestris F, Williams RC, Calvani N, Grinello D, Tucci M, Cafforio P, Dammacco F (2002) Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clin Exp Med 2:13–27PubMedCrossRef Silvestris F, Williams RC, Calvani N, Grinello D, Tucci M, Cafforio P, Dammacco F (2002) Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clin Exp Med 2:13–27PubMedCrossRef
10.
Zurück zum Zitat Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 8:508–513PubMedCrossRef Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 8:508–513PubMedCrossRef
11.
Zurück zum Zitat van Lopik T, Bijl M, Hart M, Boeije L, Gesner T, Creasy AA, Kallenberg CG, Aarden LA, Smeenk RJ (1999) Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J Rheumatol 26:60–67PubMed van Lopik T, Bijl M, Hart M, Boeije L, Gesner T, Creasy AA, Kallenberg CG, Aarden LA, Smeenk RJ (1999) Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J Rheumatol 26:60–67PubMed
12.
Zurück zum Zitat Rose LM, Latchman DS, Isenberg DA (1997) Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 6:717–722PubMedCrossRef Rose LM, Latchman DS, Isenberg DA (1997) Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 6:717–722PubMedCrossRef
13.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
14.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
15.
Zurück zum Zitat Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8–14PubMedCrossRef Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8–14PubMedCrossRef
16.
Zurück zum Zitat Alecu M, Coman G, Alecu S (2000–2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38–39:83–88PubMed Alecu M, Coman G, Alecu S (2000–2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38–39:83–88PubMed
17.
Zurück zum Zitat Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG (1998) Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?. J Autoimmun 11:457–463PubMedCrossRef Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG (1998) Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?. J Autoimmun 11:457–463PubMedCrossRef
18.
Zurück zum Zitat Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J (2004) Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 101:14883–14888, E-pub 2004 October 04 Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J (2004) Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 101:14883–14888, E-pub 2004 October 04
19.
Zurück zum Zitat Ortiz A, Lorz C, Egido J (1999) New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 12:150–158PubMed Ortiz A, Lorz C, Egido J (1999) New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 12:150–158PubMed
20.
Zurück zum Zitat Schelling JR, Nkemere N, Kopp JB, Cleveland RP (1998) Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 78(7):813–824PubMed Schelling JR, Nkemere N, Kopp JB, Cleveland RP (1998) Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 78(7):813–824PubMed
21.
Zurück zum Zitat Kacprzyk F (2002) Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies. Pol Arch Med Wewn 108:843–847PubMed Kacprzyk F (2002) Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies. Pol Arch Med Wewn 108:843–847PubMed
22.
Zurück zum Zitat Jarad G, Lakhe-Reddy S, Blatnik J, Koepke M, Khan S, El-Meanawy MA, O’Connor AS, Sedor JR, Schelling JR (2004) Renal phenotype is exacerbated in Os and lpr double mutant mice. Kidney Int 66:1029–1035CrossRefPubMed Jarad G, Lakhe-Reddy S, Blatnik J, Koepke M, Khan S, El-Meanawy MA, O’Connor AS, Sedor JR, Schelling JR (2004) Renal phenotype is exacerbated in Os and lpr double mutant mice. Kidney Int 66:1029–1035CrossRefPubMed
23.
Zurück zum Zitat Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048–1054CrossRefPubMed Silva LM, Garcia AB, Donadi EA (2002) Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 249:1048–1054CrossRefPubMed
Metadaten
Titel
Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese
verfasst von
Jia Hu Hao
Dong Qing Ye
Guo Qing Zhang
Hui Hui Liu
Hong Dai
Fen Huang
Fa Ming Pan
Hong Su
Ma Xia Dong
Hong Chen
Qian Wang
Xue Jun Zhang
Publikationsdatum
01.01.2006
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 7/2006
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-005-0616-2

Weitere Artikel der Ausgabe 7/2006

Archives of Dermatological Research 7/2006 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.